+

WO1993014778A1 - Transfert de genes ex vivo - Google Patents

Transfert de genes ex vivo Download PDF

Info

Publication number
WO1993014778A1
WO1993014778A1 PCT/US1993/000492 US9300492W WO9314778A1 WO 1993014778 A1 WO1993014778 A1 WO 1993014778A1 US 9300492 W US9300492 W US 9300492W WO 9314778 A1 WO9314778 A1 WO 9314778A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
gene
polynucleotide
vertebrate
Prior art date
Application number
PCT/US1993/000492
Other languages
English (en)
Inventor
Gary H. Rhodes
Varavani J. Dwarki
Philip L. Felgner
Jiin-Yu Hwang-Felgner
Marston Manthorpe
Original Assignee
Vical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical, Inc. filed Critical Vical, Inc.
Priority to JP5513303A priority Critical patent/JPH07503372A/ja
Priority to CA 2128616 priority patent/CA2128616A1/fr
Priority to EP93904539A priority patent/EP0625049A4/fr
Publication of WO1993014778A1 publication Critical patent/WO1993014778A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the present invention relates to methods for delivering polynucleotide to the interior of a cell of a vertebrate ex vivo.
  • this invention is directed - rapid and convenient methods for introducing genetic material into cells, which may then be returned to the vertebrate.
  • the genetic material may be introduced into the cell to correct a functional cellular defect, to augment an immune response or to express a foreign protein.
  • Gene transfer is a term that broadly encompasses methods for the introduction of gene sequences into a cell or group of cells. There are a variety of methods currently in use to introduce exogenous genetic material into cells. These methods include calcium precipitation, viral vector-mediated delivery, electroporation and liposome-mediated delivery.
  • Gene transfer in vitro is used to study the effect of a given gene and its resulting gene product on a given population of cells.
  • Early work in the field of gene transfer was directed to the areas of gene replacement and augmentation.
  • Gene augmentation includes approaches for introducing a correct copy of a mutated gene into defective cells or a copy of a foreign sequence for gene expression within that cell.
  • Gene replacement includes approaches to correct defective genetic sequences through site-specific recombination, thus permitting targeted homologous recombination for a known gene sequence. It is generally assumed that both approaches require the stable expression of exogenous polynucleotide sequences.
  • cells stably expressing the polypeptide encoded from the transfected gene are selected for further analysis.
  • stable transfectants selected for gene therapy directed to skeletal muscle and hematopoietic cells are found, in publications by Sal inen et al. and Dick et al. (Hum. Gene Ther. 2:15-26, 1991 and Blood 78:624-634, 1991 respectively) which are hereby incorporated by reference.
  • Stable expression is thought to require either stable integration or homologous recombination of DNA into the host chromosome, although there is some evidence that polynucleotide formed as episomal-like structures may be able to direct the stable expression of polypeptide as well.
  • Viral vectors encapsulated in virus particles are among the more efficient methods for gene delivery. Many viral vectors require gene integration for replication and gene expression. However, since viral vectors do integrate into the host genome with some efficiency, they may potentiate harmful recombination events that promote oncogenesis. Other methods of polynucleotide delivery include liposome-mediated transfeetion and the introduction of naked polynucleotide into tissue. Irrespective of the method for gene delivery, polynucleotide integration into the host genome can be harmful. Therefore stable transfection involving integration into the host genome will increase the probability of harmful recombination events.
  • a major challenge to gene therapy is the effective delivery of the gene sequence to the targeted tissue.
  • the efficacy of gene therapy for in vivo applications is limited by the accessibility of the gene to the target cells.
  • Viral vectors can be directed to specific cell types by incorporating cell surface binding proteins into the viral package.
  • amphotropic viral vectors or liposomes can be used to deliver gene sequences to a variety of cell types. While vectors can be introduced into the body through oral or parenteral routes, the vascular endotheliu and mucosal membranes are barriers to vector dissemination. The introduction of therapeutic genes directly into a tissue site may be more beneficial to a patient than methods relying on dissemination through oral and parenteral entry routes.
  • liposome-mediated delivery is better suited for some cell types.
  • Vectors can be injected into the tissue of interest, but experimental results indicate that the expressed protein is concentrated within those cells immediately juxtaposed to the needle tract. Cells removed but still proximate to the tract show reduced to insignificant levels of gene expression. Gene therapy would be more effective if gene expression could occur in a radius wider than cells directly adjacent to the needle tract.
  • An alternative to direct in vivo gene delivery for gene augmentation or gene replacement involves removing cells from a patient, optionally expanding these cells in culture, transfecting the cells and identifying stable transfectants. Following identification of stable transfectants, the cells are optionally expanded and returned to the host. This procedure has been used most successfully to transfect cells of hematopoietic origin.
  • the conditions used to select stable transfectants also selects for cells able to survive in culture.
  • Cell survival in vitro does not translate into improved cell survival in vivo.
  • cells adapted to culture or cells expanded in culture may not be able to survive in vivo.
  • a method that minimizes cell time in culture will reduce the likelihood that cell changes occur in vitro.
  • Current gene therapy procedures are labor intensive and require a high level of technical expertise.
  • gene therapy is typically restricted to large medical research centers with highly sophisticated technical support. Individuals lacking access to these centers are not likely to benefit from technically intensive genetic th ⁇ rapies.
  • a procedure to introduce a gene of interest into host cells with minimum turn around time, that could be performed rapidly and routinely at a doctor's office, a medical clinic or local hospital would allow greater numbers of people to benefit from gene therapy.
  • the method disclosed herein permits cells from a given tissue to be processed, treated with the desired gene and returned to the patient in a timely manner. Cell replication and selection are not required. Thus the level of technical skill, the time and the cost of the gene therapy procedures is reduced.
  • Figure 1 Three-dimensional bar graph of results from the microtiter transfection procedure.
  • Figures 2a-2d Three-dimensional bar graphs comparing cell density to transfection efficiency.
  • Figure 3 Graph of IgG antibody titer to HIV gpl20 immunized cells ex vivo.
  • the present invention provides a method for delivering a polypeptide to the interior of a cell of a vertebrate ex vivo comprising the steps of removing live cells from the vertebrate, contacting the live cells with a preparation comprising an effective amount of polynucleotide operatively coding for the polypeptide and lipid effective to deliver the polynucleotide into the cells, and returning the cells to the vertebrate within 48 hours after the contacting step so that the live cells express the polynucleotide in vivo.
  • the present invention does not require post-transfection selection and expansion steps. Thus, the entire procedure can be completed in a number of hours, instead of weeks.
  • Another aspect of the present invention is a method for preparing transfected cells for use expressing a polypeptide in a vertebrate, comprising the steps of removing live cells from the vertebrate, and transfecting at least " some of the live cells by contacting them with a preparation comprising an effective amount of a polynucleotide operatively encoding the polypeptide and a transfection-facilitating lipid, the preparation being effective to deliver a substantial amount of the polynucleotide into the cells by contact therewith within 48 hours, and suspending the transfected cells in a pharmacologically acceptable carrier for introduction into the vertebrate, in the absence of a selection step to separate or expand the transfected cells.
  • the removing step additionally comprises substantially separating the cells from the surrounding extracellular matrix.
  • the method may include freezing the cells within 48 hours after the contacting step.
  • the peptide is adapted to treat a disease of the vertebrate caused by a functional gene deficiency.
  • the polynucleotide is adapted to express the polypeptide in the live cells. The expression of the polynucleotide by the cells may be transient, or may persist for a substantial length of time.
  • the polypeptide is an immunogenic polypeptide in the vertebrate.
  • the vertebrate (which may be a mammal, including a human, a bird, or some other vertebrate) develops an immune response against the immunogen after the transfected cells are reintroduced.
  • This method may be used to immunize the animal.
  • Cells that may be used include (for example) white blood cells, myoblasts, and bone marrow cells.
  • the present invention includes a medicament prepared in accordance with any one of the foregoing methods.
  • a method for delivering a polypeptide to a vertebrate in vivo comprising the step of injecting or implanting such a medicament into a vertebrate.
  • the cells used in this method preferably include cancer cells, white blood cells, bone marrow cells including stem cells and myoblasts.
  • the polynucleotide preferably operatively encodes lymphokine.
  • the methods disclosed teach a procedure to remove a tissue or cell sample from a patient, contact the cells of the sample with the desired gene ex vivo and return the cells to the patient preferably within less than 40 hours after removing the sample from the patient.
  • the procedure delivers a polynucleotide operatively coding for a polypeptide to the interior of a cell of a vertebrate.
  • polypeptide and “protein” are used interchangeably within this patent application.
  • exogenous polypeptide is used to differentiate protein naturally occurring in the cell from protein introduced into the cell using the methods of this invention.
  • removing is used to describe any method known to those with skill in the art to obtain a sample of live cells from a vertebrate patient. Methods to remove a live cell sample include but are not limited to venipuncture, cell scraping, and biopsy techniques that include punch biopsy, needle biopsy and surgical excision.
  • the term “contacting” includes methods to introduce polynucleotides into a cell. These methods include transfecting methodologies including electroporation, liposome-mediated transfection, calcium phosphate precipitation and DEAE-dextran.
  • returning includes methods known to those with skill in the art to replace cells in the body. These include, but are not limited to, intravenous introduction, surgical implantation and injection.
  • a method comprises removing live cells from a vertebrate patient, substantially removing the cells from the surrounding extracellular tissue, contacting the live cells with a preparation comprising an effective amount of polynucleotide and returning the cells to the patient.
  • the cells are isolated, exposed to the gene of interest, and returned directly to the host with minimal time in culture to reduce the potential for cell change in vitro.
  • Some of the cells express the desired gene transiently, others stably; however, with a minimum turn around time, the cells are more likely to survive in vivo. Whether stable or transient expression is achieved, the result is beneficial. If needed, the therapy can be repeated to maintain the desired level of exogenous gene expression.
  • Transient gene expression in vitro is generally defined as temporary gene expression that diminishes over time under selective conditions. In vivo transient expression can more broadly be defined as gene expression occurring over periods of less than one year to periods as short as one week or one month.
  • the gene therapy application the vector construct, whether or not chromosome integration has occurred, the cell type and the location of cell implantation following transfection will all influence the length of time that a particular gene is expressed.
  • the methods discussed herein teach one of skill in the art to introduce gene sequences such that a variety of cells from a variety of tissues can be treated ex vivo and rapidly returned to a host for gene expression without selection for stable transfectants.
  • the therapy can be used to express exogenous polynucleotide in a variety of tissues not readily accessible by other gene therapy means.
  • liver cells can be transfected with the LDL receptor to reduce serum cholesterol in vivo, and muscle can be removed to treat the cells with the defective gene product involved in Duchennes muscular dystrophy.
  • Progenitor cells from the he atopoietic system can be treated at a predifferentiated stage to correct hereditary disorders such as beta-thalassemia.
  • the method is contemplated to be particularly useful for the treatment of diseases due to a functional gene deficiency.
  • the polynucleotide encoding exogenous polypeptide codes for the polypeptide deficient or malfunctioning in that particular genetic disease.
  • the transient expression of the gene product can be advantageously used to promote an immune response.
  • viral diseases can be treated by interferon expression and cytokines can be used to stimulate the immune system to react against foreign antigens or cancers.
  • foreign protein can be expressed transiently from target cells to generate an immune response.
  • Biopsy and Tissue Processing A biopsy or cell sample is preferably obtained from a patient in need of gene therapy. However it is additionally contemplated within the scope of this invention that the treated cells could be derived from a secondary source such as a cell line or a cell donor. The cell sample is preferably obtained from a tissue where gene expression would be most advantageous.
  • the cell sample may be derived from a variety of tissues including skin, liver, pancreas, spleen, muscle, bone marrow, nervous system cells, blood cells, and tumor cells.
  • tissue including skin, liver, pancreas, spleen, muscle, bone marrow, nervous system cells, blood cells, and tumor cells.
  • the type of tissue and location of that tissue will suggest the best method of tissue sampling.
  • Biopsy of formed tissue may be obtained by needle, catheter, punch biopsy or surgical excision. For example, a skin biopsy may be best obtained by a skin punch, while a liver biopsy may be best obtained by a needle biopsy.
  • the size and quantity of biopsy is determined by the level of cell recovery following tissue processing. It is estimated that the transfection procedure can be optimized for the transfection of as little as 50-100 cells.
  • the biopsy size should be adjusted to account for cell recovery.
  • a skin biopsy of 0.5 cm 2 should produce a minimum of 2500--5000 cells. Low cell recovery from a given biopsy may necessitate a larger biopsy size or a change in the cell dissociation procedure for a given tissue.
  • a simple blood draw into a heparinized, EDTA, or citrate tube can be processed by centrifuging at 1000 rpm for 10 min.
  • the buffy coat is drawn into a Pasteur pipette and the cells contained therein are washed to remove serum, red blood cells, and debris. These cells are ready for gene therapy.
  • the cells are separated from surrounding supportive tissue or extracellular matrix.
  • a skin biopsy is enzymatically digested to dissociated the cells from their extracellular matrix.
  • the following procedure is only one of many procedures for tissue dissociation. This particular procedure is useful for skin, kidney and lung tissue dissociation.
  • the biopsy is removed from the patient it is placed in sterile saline and washed to remove blood and debris.
  • the tissue is minced with a scalpel or single edge razor blade, in a small amount of Hanks Balanced Salt Solution (GIBCO, Grand Island, New York) . This permits the relative pH of the tissue sample to be monitored during processing. Maintaining physiologic pH is important to cell survival.
  • the mincing is performed for approximately 10 minutes or until the tissue resembles a thick paste.
  • the paste is transferred to a small Erlenmeyer flask or beaker (5 ml.) and the volume of cell paste is approximated. Three volumes of a mixture of 0.25% trypsin/ ImM EDTA (GIBCO) and 1% wt/vol.
  • collagenase B (Boehringer Mannheim, Indianapolis, Indiana) is added to the cell paste.
  • the flask is covered with foil and placed on a rotational platform in a 37° C incubator for 15-30 min.
  • a sterile small magnetic stir bar is added to the sample and the flask is placed on a magnetic stir plate.
  • the sample is monitored every 10 min both to maintain the pH and to monitor tissue dissociation.
  • fetal calf serum or albumin is added, and the sample is passed through three layers of sterile cheese cloth to remove connective tissue fragments. The liquid that passes through the cloth is checked for visible cell clumps.
  • the clumps are spun down (1200 rpm, 5 min) and the trypsinization/collagenase procedure is repeated. The enzymatic solution is washed away from the cell suspension and the cells are washed and transferred into the appropriate size vessel for transfection.
  • Methods for the dissociation of other tissues may employ different enzyme preparations.
  • Other enzymes used in tissue dissociation include Versene, pancreatin and other collagenases.
  • Biopsy samples from tissues that have minimal connective tissue will not require collagenase treatment. For these samples, trypsin digestion may be sufficient.
  • trypsin mediated dissociation may be too harsh.
  • EDTA or other chelators will sufficiently dissociate the tissue while maintaining cell survival.
  • mincing or aspiration may generate a cell suspension without enzymatic treatment.
  • tissue dissociation may not be required; the biopsy sample is transfected directly without further manipulation.
  • a uniform cell population is preferred. The cells are first dissociated from a biopsy or blood sample and then further separated from other cell types. There are a variety of methods known to those with skill in the art for removing a particular cell type from a mixed suspension of cells.
  • Cell types can be differentiated from one another by their density or size. For example, mesh screens, Ficoll or sucrose gradient centrifugation can be used to separate one cell population from another. Cells can additionally be separated on the basis of their adherent properties. For example, fibroblasts will adhere and settle onto plastic more quickly than epithelial cells. Populations of cells can also be separated from one another by virtue of surface protein. Lectins or antibodies can be used to selectively separate on population of cells from another either using panning (passin cells over a surface with bound lectin or antibody) , colum chromatography or fluorescent activated cell sorting.
  • cells from a blood sample ar separated in a device (The Cellector, Applied Immune Sciences, Menlo Park, California) which comprises multiple polystyren plates to which monoclonal antibodies, which bind selectivel to specific cells, have been permanently attached.
  • a device The Cellector, Applied Immune Sciences, Menlo Park, California
  • targeted cells remain attached to the polystyrene surface, while other cells pass through the device.
  • the captured cells can then be released by mechanical or chemical means.
  • the washed and dissociated cells can be stored for up to 24 h or longer in culture. However, the cells are preferably transfected immediately following tissue dissociation and cell purification. If there is a delay between cell isolation and transfection it is worthwhile to return the cells to a nutritive environment.
  • the cells can be stored in tissue culture medium with a composition compatible to the particular cell type. Typically Eagles (EMEM) or Dulbecco's minimum essential medium (DMEM) with 10% fetal calf serum (FCS) or fetal bovine serum (FBS) and an antibiotic solution (Fungi Bact Solution, Irvine Scientific, Irvine, California; contains penicillin, streptomycin and fungizone) are used to maintain the cells ex vivo.
  • EMEM Eagles
  • DMEM Dulbecco's minimum essential medium
  • FCS fetal calf serum
  • FBS fetal bovine serum
  • antibiotic solution Ferungi Bact Solution, Irvine Scientific, Irvine, California; contains penicillin, streptomycin and
  • the invention disclosed herein can employ either DNA or
  • RNA DNA delivery may be preferred when stable or more prolonged gene expression is favored. However, either RNA or
  • DNA gene delivery can be used for transient gene expression applications. As noted, the method makes no selection for transient versus stable expression. However, without selection, it is likely that the majority of the cells will be transiently transfected. Transient expression permits gene expression for periods of hours or months. While repeated therapies may be required for some applications, the patient nevertheless benefits from the effect of gene-expression. Like a drug, the dosage of polynucleotide and the number of delivery sites to the tissue can be monitored and adjusted accordingly. DNA encoding the therapeutic gene may be circular or linear and should contain regulatory elements that facilitate expression in the target cells. Current progress in molecular biology is directed to the identification and isolation of tissue specific promoters.
  • tissue specific promoters As these tissue specific promoters are identified, they may be encorporated into the gene expression vector and used for ex vivo gene therapy stratagies in a particular tissue. Similarly more promiscuous promoters may be selected for a given application based on their promotional strength. Thus the actin promoter, the Rous Sarcoma virus (RSV) promoter or the Myo D promoter may be used for myoblast and muscle transfection.
  • the cytomegalovirus (CMV) immediate early (IE) gene/enhancer (Foecking et al., Gene 45:101 (1986) hereby incorporated by reference), the RSV promoter/enhancer (Wolff, J.A. et al.
  • transfected DNA may be used for transfection in myoblasts followed by intramuscular injection for expression in mature muscle fibers.
  • the transfected DNA should additionally contain regions to mediate ribosome binding, polyadenylation signals and include enhancer regions to facilitate in vivo gene expression.
  • RNA encoding the polypeptide of interest should similarly contain appropriate promoter elements and ribosome binding sites.
  • the RNA is capped or stabilized to promote translation and to minimize exonuclease activity.
  • RNA in cationic-mediated gene transfer is described in a publication by Malone et al. (Proc. Natl. Acad. Sci.USA 86:6077-6081 (1989) , hereby incorparated by reference) .
  • the mRNA can include particular 5' sequences that permit expression of uncapped mRNA.
  • some members of the picornavirus family including encephalomyocarditis virus (EMCV) have mRNAs that are naturally uncapped, yet they are translated and stable.
  • EMCV encephalomyocarditis virus
  • a 650 bp (base pair) sequence in the 5' untranslated region provides a ribosome binding site that permits ribosome binding without a capping structure (Elroy-Stein, et al . Proc. Natl. Acad. Sci. USA 86:6126-6130 (1989) , hereby incorporated by reference) . These sequences can be used as replacements for the cap structures.
  • the "contacting" step of this invention includes methods for introducing polynucleotide sequences into target cells.
  • the methods include calcium phosphate precipitation, DEAE- dextran, electroporation and liposome-mediated gene transfer.
  • liposome-mediated gene transfer is used to introduce the polynucleotide into the target cells.
  • Liposo es comprise a phipathic lipids forming hollow lipid vesicles. They have been used in vitro as a mechanism for introducing genetic sequences into tissue culture cells (Mannino, R.J., Foul -Fogerite, S. , Biotechniques 6:682-690, 1988) . Lipids forming liposomes may be positively charged (cationic) , negatively charged (anionic) or neutral.
  • DOTMA a positively charged synthetic cationic lipid, N-[l-92,3-dioleyloxy)propyl]-N,N,N-trimethylammoniumchloride
  • DNA, RNA, a modified polynucleotide or a combination thereof can be introduced directly into the cell cytoplasm (Malone et al. Proc. Natl. Acad. Sci. (USA) 86:6077-6081, 1989) .
  • LipofectinTM (GIBCO/BRL, Gaithersburg, Maryland) is used in vitro for nucleic acid transfection procedures.
  • LipofectinTM consists of 0.5 mg/ml DOTMA and 0.5 mg/ l dioleoylphosphatidyl ethanolamine in sterile water.
  • DOTMA the cationic lipid component of LipofectinTM, is a diether lipid.
  • Suitable cationic lipid species comprise known cationic lipids, such as 1, 2-bis (oleoyloxy) -3- (trimethylammonio)propane (DOTAP) orN-(w, w-1-dialkoxy) -alk- 1-yl-N, N, N-trisubstituted ammonium surfactants, or complex cationic lipids having similar structures and properties or mixtures of these.
  • known cationic lipids such as 1, 2-bis (oleoyloxy) -3- (trimethylammonio)propane (DOTAP) orN-(w, w-1-dialkoxy) -alk- 1-yl-N, N, N-trisubstituted ammonium surfactants, or complex cationic lipids having similar structures and properties or mixtures of these.
  • DOTAP 1, 2-bis (oleoyloxy) -3- (trimethylammonio)propane
  • Particularly preferred cationic lipids including those cationic lipids postulated to be more readily degradable in vivo are those disclosed in a co-pending U.S. Application No. 686,746 filed April 19th, 1991 by Feigner et al. , which is hereby incorporated by reference.
  • DORI DL-1 , 2-dioleoyl-3-dimethylaminopropyl-5- hydroxyethylammonium
  • DORIE DL-1, 2-0-dioleyl-3- dimethylaminopropyl-3-hydroxyethylammonium
  • DORI ester/ether compounds DL-1-O-oley1-2-o1ey1 -3 - dimethylaminopropyl-_3-hydroxyethylammonium or DL-l-oleyl-2-O- oleyl-3-dimethyl-aminopropyl- ⁇ -hydroxyethylammonium
  • othe derivatives having the general formula
  • Y 1 and Y 2 are the same or different and are -O-CH-,-, -O- C(O)-, or -0-;
  • R 1 and R 2 are the same or different and are H, or C. to C 23 alkyl or alkenyl ;
  • R 3 and R 4 are the same or different and are C 1 to C 24 alkyl, or H;
  • R 5 is C 1 to C 24 alkyl straight chain or branched chain;
  • R 6 is -C(O) -(CH 2 ) m -NH-, a di ⁇ ninocarboxylic acid which i alkyl, aryl, or aralkyl, or -C(0) -(CH 2 ) m -NH- linked to said diaminocarboxylic acid, or is absent;
  • R 7 is H, spermine, spermidine, a histone, or a protein with DNA-binding specificity, or wherein the amines o the R 7 moiety are quaternized with R 3 , R 4 , or R 5 groups; or
  • R 7 is an L- or D-alpha amino acids having a positively charged group on the side chain, said amino acids comprising arginine, histidine, lysine, ornithine or derivatives thereof, or the same amino acids wherein th amine of the R 7 moiety is quaternized with R 3 , R 4 or R groups; or
  • R 7 is a polypeptide selected from the group consisting of L- or D-alpha amino acids, wherein at least one of the amino acids residues comprises arginine, histidine, lysine, ornithine, or derivatives thereof; is 1 to 8 ; is 1 to 18 ; and X is a non-toxic anion.
  • Non-toxic anions described herein may be those of pharmaceutically non-toxic acids including inorganic acids and organic acids. Such acids include hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, benzoic, citric, glutamic, lactic acid and the like.
  • DOTMA N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium
  • DOTMA N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium
  • lipids may be added to the cationic lipid of choice.
  • DOPE dioleoyl phosphatidyl ethanolamine
  • DOPC dioleoyl phosphatidyl choline
  • the ratios of lipids may vary to include a majority of cationic lipid in combination with cholesterol or mixtures of lyso or neutral lipids. Preferred lipid formulations will be detailed in the examples below.
  • cationic lipid-mediated DNA transfection is discussed.
  • Examples of cationic lipid-mediated transfection relating to specific applications of this invention are discussed in Examples 1 and 2.
  • LipofectinTM is a commercially available cationic lipid.
  • the lipid molecules and/or other lipid components are solubilized in chloroform and dried overnight with a vacuum pump to remove trace amounts of chloroform.
  • the lipid film is next hydrated with sterile purified distilled deionized water and the sample is sonicated at 10°C to clarity. Mixtures of lipid are combined with polynucleotide for transfection. These techniiiques are known to those with skill in the art.
  • tissue dissociation methods available along with different cell purification schemes. Biopsies and cells may be frozen before of after tissue dissociation.
  • Dissociation and purification procedures should be performed as rapidly and expediently as possible after biopsy to maximize cell viability.
  • the cells are transfected.
  • the transfected cells are preferably returned immediately to the patient without expansion or selection in culture.
  • the biopsied tissue can be dissociated, treated with the desired polynucleotide, and frozen without expansion or selection in culture. Samples can be thawed as necessary for future treatments. Similarly, a portion of the frozen cells can be thawed and assayed for transfection efficiency or for gene expression. There are a variety of methods known to those with skill in the art for freezing cells.
  • Standard methods for freezing cells involve freezing cell suspensions in 5-20% FCS with 2-7% DMSO or glycerol. The cells are placed at -70°C overnight and stored at or near -120°C. Modifications of this standard technique are well known to those with skill in the art.
  • the ex vivo procedure can be used to activate the immune system.
  • An effective amount of polynucleotide is delivered to the appropriate cells and expression of the polypeptide encoded by the polynucleotide results in activation of the immune system.
  • This particular strategy has a variety of uses.
  • the most direct use is to stimulate the humoral and cellular immune system.
  • a gene operatively encoding a polypeptide of interest is introduced into a population of cells obtained from a blood sample or tissue sample. These cells are returned to the patient.
  • the expression of a foreign gene in the host stimulates cell presentation to the immune system resulting in a humoral response from B lymphocytes and a cellular response in the T cell population.
  • expression of a foreign gene in a given population of immune system cells can directly stimulate immune responses.
  • Example 5 and 6 illustrate an approach to the activation of the immune system which allows better control over cellular immune responses against virus infected cells and cancer cells in vivo than traditional " immunization protocols.
  • a growing body of data indicate that intracellular antigen synthesis is required for optimal presentation of antigens to the cellular arm of the immune system. This is because antigen presentations in the context of major histocompatibility complex (MHC) class I protein is best achieved when antigen is processed together with MHC class I protein in the Golgi apparatus.
  • MHC major histocompatibility complex
  • the benefit of intracellular antigen synthesis to the potency of an immune response helps to explain the difficulties associated with the generation of functional cellular immune responses against recombinant antigens by conventional systemic, extracellular injection of subunit vaccines.
  • retrovirus transformed primary cells or syngeneic cells lines expressing intracellular antigen
  • Our results indicate that the non- retroviral mediated approach can similarly " bypass this restriction, and we anticipate that it will be preferred, for regulatory reasons, to approaches which require viral vectors.
  • This ex vivo gene therapy will be a useful technique for generating an immune response.
  • Transient expression of therapeutic polypeptide is employed to transiently introduce gene product into the body as a therapeutic drug.
  • Another embodiment of the invention involves the stimulation of the immune system to recognize a given population of cancer cells as foreign.
  • tumor cells are removed from a patient, transfected with a gene, and the cells are returned to the patient within 48 hours following transfection. In a preferred embodiment, the cells are immediately returned to the patient.
  • the immune system then recognizes those particular cancer cells expressing the exogenous polypeptide as foreign. Stimulation of an immune response in the general locale of the cancerous tissue increases the likelihood that untreated tumor cells will additionally be recognized as foreign, thereby generating generalized tumor regression.
  • a number of — immunogenic proteins could be used to stimulate the immune system toward cancerous cells. Both endogenous genes, such as those of the major histocompatibility complex, and foreign antigen may be useful.
  • lymphokine in the tumor cells or in other selected cells of the body.
  • Lymphokines in general, and IL-2 in particular, are potent immune system stimulators. Lymphokine expression can be used to activate endogenous lymphokine activated killer cells (LAK cells) .
  • LAK cells endogenous lymphokine activated killer cells
  • IL- 2 stimulates the differentiation of null cells to become LAK cells. These cells are known to attack a variety of cancers and stimulation of their cell killing activity is enhanced by exogenous IL-2.
  • a second cell type, tumor-infiltrating lymphocytes (TIL) is also stimulated by IL-2 and has been found to be more effective than LAK cells in promoting tumor regression.
  • TIL tumor-infiltrating lymphocytes
  • other cytokines are identified that are directly cytotoxic to tumor cells.
  • cytotoxic T-cells may also increase the clearance of latent viral infections and facilitate the destruction tumorigenic foci. Improved regulation of helper and suppressor T-cell populations by this approach may ultimately lead to improved methods for controlling autoimmune disorders including rheumatoid arthritis.
  • a muscle biopsy is used to isolate muscle myoblasts.
  • Patient myoblasts can be isolated following the techniques of Blau et al. (Proc. Natl'. Acad. Sci. USA 78: 5623-5627, 1981, which is hereby incorporated by reference) .
  • Myoblasts are readily obtained from muscle without substantial inconvenience to the patient.
  • the muscle myoblasts are then transfected ex vivo following the methods disclosed herein and returned within 48 hours after transfection to the muscle or to other tissues of the patient.
  • Myoblasts can additionally be stored or frozen for a time without a significant loss in cell viability or a significant change in cell phenotype.
  • myoblasts When myoblasts are reintroduced back into muscle, they are capable of fusing with the available mature myofibers.
  • myoblast delivery is a particularly efficient method for gene delivery to muscle cells. Since the myoblasts are readily isolated and conveniently obtained from muscle tissue of the patient, there is no risk of tissue rejection. Transient gene expression is more likely to be sustained over time from repeated therapies in autologous cells.
  • Another important advantage to myoblast transfection is that muscle tissue is accessible to injection and underlies most surfaces of the body, thus the transfected cells can be injected in multiple locations as often as needed.
  • muscle specific promoters like MCK (Jaynes et al. , supra)
  • gene product expression can be restricted to mature muscle fibers.
  • the muscle cells thus express the desired polynucleotide sequence.
  • stable myoblast transfectants injected into muscle tissue express their gene product into the blood stream (Hoffman, M. Science 254: 1455-1456, 1991) .
  • any number of therapeutic agents could be used to treat the cell sample from a patient ex vivo.
  • polynucleotide could be transiently expressed from the isolated cells, any number of agents could be added to the cells to provide a transient therapeutic effect.
  • polynucleotide nucleoside analogs, riboenzymes, antisense polynucleotide, or other pharmaceuticals can be delivered to the cells. Reintroduction of treated cells
  • the cells are washed, concentrated and returned to the patient.
  • the cells may be returned directly to their tissue of origin, or for some applications, the cells can be returned to a second location either within the tissue of origin or at a location distant from the tissue of origin.
  • a large bore needle (18 gauge or larger) is preferably used to return cells to the body. Any bore size may be used that does not destroy the cells or restrict cell passage into the tissue. It may be beneficial to introduce the treated cells into multiple locations within a given tissue. For example in Duchenne's muscular dystrophy, multiple injections of treated cells will advantageously disperse the gene product throughout the tissue.
  • the intact biopsy may be replaced by surgical implantation.
  • Other cells such as hepatocytes, can be introduced back into their organ of origin by injection into a vein leading into that organ. Methods to return treated cancer cells to a patient will depend on the cancer type. Injection of autologous transfected cancer cells into either a tumor mass or bone marrow is possible. Expression of an MHC protein, a foreign protein or an immune stimulating protein can stimulate immune responses directed to both the treated and untreated tumor cells, thereby reducing or clearing the tumor mass.
  • Other transfected cancer cells of he atopoietic origin may be introduced directly into the blood stream.
  • Cells from hard tissue tumors may be replaced directly into a tumor mass to elicit tumor regression. This may be performed through external injection or internal injection using catheters or the like.
  • the reagents necessary to perform the gene therapy are provided in kit form.
  • kit form the procedures that have been outlined in Example 1 and 2 for optimization of gene transfection into a particular cell type are used to determine the optimal combination for transfection of a particular gene into a cell obtained from a particular tissue.
  • a transfecting dose of the gene is supplied as either RNA or DNA complexed to or separate from the cationic lipid or lipid transfecting reagent.
  • Equipment required for a given therapy may additionally be supplied, including biopsy tool, balanced salts, medias, wash buffers, and tissue dissociation tools.
  • the optimized procedure is reduced to a routine laboratory procedure requiring minimal laboratory manipulation.
  • the technician receives a biopsy from the physician, a blood sample or a skin punch.
  • the sample is processed according to kit directions.
  • the appropriate number of cells for the particular regime (as optimized) is placed into transfection wells and transfected with the gene of interest. Following an incubation and wash period the cells are inserted, preferably by injection or surgical implantation, back into the patient.
  • Standard methods for cell transfection require in excess of 30,000 cells per transfection.
  • a biopsy or cell sample must first be expanded in culture to provide a sufficient target population for transfection.
  • efficient transfection and gene expression is possible using cell numbers easily isolated from a standard biopsy or blood draw.
  • earlier methods required that the technician select those cells stably expressing the gene of interest following transfection and these cells were further expanded.
  • the invention disclosed herein does not require cell expansion prior to transfection nor cell selection following transfection. Cells are immediately frozen or returned directly to the patient. This reduces the required technician time and expertise such that gene therapy can become a widely available medical procedure.
  • transient expression is often desirable in the practice of the present invention.
  • This major conceptual difference from the prior art affectively permits the physician to use the gene of interest as a drug. ' Thus a gene can be administered periodically; the dosage can be adjusted, and the effect is ultimately transient. None of these benefits are available through conventional gene therapy.
  • Each gene therapy regime should be optimized to facilitate maximum transfection efficiency. Once the optimum conditions are obtained for a particular cell type, cationic lipid reagent and polynucleotide, then individual wells containing as few as 50-100 cells can be transfected. The optimization scheme provided below uses 5,000 to 40,000 cells per well but can be scaled down for optimization of techniques employing fewer cells. Cationic Lipid Dilution Scheme
  • Dispense 70 ul of Opti-MEM in each well Load 70 ul of 80 ug/ml DNA per well to the first 9 wells of row 1.
  • RNA transfections are identical to the DNA methodology, with the exception that the optimum quantity of LipofectinTM required per unit mass of RNA will typically be somewhat less than that for DNA transfections and the harvest time for gene expression is 8 hours after addition of the message. These details may be worked out using the methods described above, substituting RNA for DNA. It is important to recognize that messages that are translatable in in vitro reticulocyte lysate systems, may not be active on intact cells. Intracellular activity requires message that is flanked by untranslated elements. B. Malone et al.
  • the cells were lysed with 50 ul lysis buffer (0.1% Triton X-100, 250 mM Tris pH 8.0) per well. The plate was frozen at -70°C before assay. 50 ul of PBS containing 0.5% BSA was added to each well except for column 12. Serial dilutions of beta- galactosidase standard were prepared in PBS containing 0.5% BSA and added to the last column, (eg. 50 ul of 50000, 25000, 12500, 6250, 3125, 1562, 781, 390 pg/ml standards). 150 ul substrate was added to the wells.
  • 50 ul lysis buffer (0.1% Triton X-100, 250 mM Tris pH 8.0
  • the substrate consisted of either 1 mg/ml CPRG (chloroform red galactopyranoside) or 2 mg/ml of ONPG (ortho-nitrophenol galactopyranoside) in beta- gal buffer.
  • Beta-gal buffer contains 60 mM sodium dibasic phosphate buffer, pH 8, ImM magnesium sulfate, 10 mM " potassium chloride and 50mM betamercaptoethanol.
  • the substrate was added to each well and the results were read at 580 n for the CPRG assay or 405 nm for the ONPG assay on a microtiter reader after color development.
  • the CPRG assay was more sensitive than the ONPG and was also less affected by light scattering from cell debris.
  • the assay can also be performed using an alkaline phosphate reporter gene with p- nitrophenol phosphate as a substrate. In addition it can be adapted to an ELISA format by transferring a portion of the cell lysate to antibody coated plates.
  • the -data in Figure 1 display the outcome of a typical transfection assay using this procedure.
  • the bars on the 3D plot represent the level of beta-galactosidase expression in individual wells of the microtiter plate.
  • the cells in each well were treated differently with respect to the levels of DNA and cationic lipid present in the well.
  • Along one axis of the two dimensional matrix are shown serial dilutions of cationic lipid, and the other axis has serial dilutions of DNA.
  • Optimal activity occurs near the middle of the plate.
  • the decline in activity at high cationic lipid concentrations is attributed to toxicity of the lipid; this is supported by direct observations of the cells under the microscope which show that the cells can be severely affected by high concentrations of lipid.
  • the DNA and cationic lipid concentrations must be simultaneously varied in order to obtain optimal transfection activity.
  • a balance of cationic lipid and polynucleotide is required for efficient delivery since cationic lipid can be
  • a comparison of transfection activity among different cell types reveals a substantial variation in the maximum levels of protein expression.
  • Mouse L cells produced 400 fold less gene product than BHK cells.
  • the differences in transfection efficiencies may be due to the efficiency of cationic lipid mediated cell fusion.
  • the intracellular polynucleotide degradation capacities may vary, or uptake from the cytoplasm into the nucleus may differ.
  • Three different mouse muscle cell lines were successfully transfected at the same level as COS7 cells and primary rat brain astrocytes were also transfected at these concentrations.
  • Lac Z expression in COS-7 cells replaced in ⁇ vivo.
  • Cationic lipid vesicles of a 1:1 mixture of DORI/DOPE were diluted to 0.747 mM in sterile water. 20,000 COS 7 cells/well were seeded in a 96 well microtiter plate. In a second plate 60 ul Opti-MEM with 54 ul of 0.747 cationic lipid was combined. Serial two-fold dilutions were prepared in Opti-MEM to obtain a final cationic lipid concentration of 84 uM. The DNA was serially diluted in Opti-MEM to a final concentration of 60 uM.
  • Equal volumes of cationic lipid and DNA were mixed to produce a final concentration of 42 uM lipid and 30 uM DNA to achieve a Lipid:DNA ratio of 1.39.
  • the media or balance saline was removed from the cells and 100 ul of the cationic lipid/DNA complexes was added to the cells.
  • the cells were incubated at 37°C in 10% C0 2 for 4-6 hours. Following transfection, the cells were washed. These cells are then injected subcutaneously. into african green monkeys. Forty-eight hours later the tissue is removed and sampled for beta-galactosidase activity.
  • IgG anti-gpl20 antibodies were detected 12 days after injection and levels peaked 28 days post injection using a standard Elisa known to those of skill in the art and employing HIV infected H9 cell lysates.
  • Antibody titers were relatively high with an average serum titer of 1/20,000.
  • the cells were transiently transfected with the gene for the antigen. No prolonged tissue culture selection was required to produce the observed humoral response. Animals may require a second injection of plasmid to boost the immune response (see example 6) ; however a boost was not required for a high titered response to gpl20 in mice.
  • two plasmids are prepared using a pBR322 based plasmid with RSV regulatory elements linked to either luciferase (control) or the immunodominant fragment of Schistosome protein Sj23 (Wright et al., J. Immunol. 147:4338-4342, 1991 and Davern et al., Mol. Biochem. Parasitol. 48:67, 1991, hereby incorporated by reference) .
  • Plasmid DNA containing polynucleotide encoding Sj23 is prepared in a 1:1 mixture of DORI/DOPE. An equivalent concentration of 150 ⁇ q plasmid DNA with cationic liposomes is bilaterally injected into each thigh of Balb/C mice.
  • mice receiving pRSV-luciferase control One half of the mice receiving pRSV-luciferase control and the other half receiving pRSV-Sj23.
  • a second vaccination into one thigh is repeated twenty-two days after primary injection.
  • Schistosoma mansoni is used to challenge the animals 12 days after the second injection.
  • Anim ⁇ s are bled' weekly for one monthly following the challenge. Titers are compared between the two animals to determine whether the antibodies generated from the immunodominant region of the schistosome protein protect against virus challenge.
  • Example 7 illustrates a method to express exogenous polynucleotide sequences in muscle cells.
  • myoblasts are treated with a gene of interest and introduced back into whole muscle.
  • the mouse myoblast cell lines used in the study were C2, G7, and G8.
  • C2 is a mouse myoblast cell line established from normal adult C3H mouse leg muscle (Nature 270: 725-727; Science 230: 758-766, hereby incorporated by reference).
  • G7 and G8 are mouse myoblast cell lines isolated from the hind limb muscle of a fetal Swiss Webster mouse. G7 is tumorigenic whereas G8 is non-tumorigenic (Science 196:995- 998, 1977, hereby incorporated by reference).
  • transient transfections were performed using the pSV2-LacZ reporter construct with DORIE/DOPE concentrations optimized from Example 1. These cells were implanted into the hind limb of Balb C mice. Tissue sections from injected muscle are stained using antibody to LacZ. Similarly, blood samples are assayed by ELISA for LacZ protein. All transfected cells are tissue positive for LacZ and myoblast cell lines G7 and G8 are additionally serum positive. The results indicate that the myoblasts can be transfected in vitro using methods applicable to other commercially available cell lines.
  • EXAMPLE 8 Delivery of Human ⁇ .,-antitrypsin to an Animal by in vitro Transfection and Replacement of Autologous Hepatocytes
  • Hepatocytes are isolated from a liver sample obtained by partial hepatectomy, placed in culture medium and returned to the animal after transfection essentially as described by Kay, M. et al., Proc. Natl. Acad. Sci USA 89:89-93 (1992).
  • Cationic lipids for transfection are a 50:50 mixture of DORI:DOPE, and cells are transfected by means of a DNA plasmid vector pSVZ construct, comprising the human ⁇ .,-an itrypsin cDNA under transcriptional control of the cytomegalovirus promoter. Concentrations and ratios of transfection lipids and DNA are determined according to the scheme of Example 2.
  • the transfected cells are rinsed in basal media comprising 2-10% animal serum, and resuspended in the same solution at a concentration of 10 6 -10 7 cells/ml.
  • the solution containing the transfected cells is then injected into the portal circulation of the liver of the same animal, preferably by means of an infusion pump at a rate of about 0.5 to 2.0 ml/min.
  • the in vivo secretion of human ⁇ .,-antitrypsin is followed by assay of serum levels of human --..,-antitrypsin.
  • the cells are transfected by means of a DNA plasmid vector pRSV, pSV2, or pCMV construct, comprising the human nerve growth factor cDNA under transcriptional control of the early SV40 or immediate early CMV promoters. Following incubation at 37°C in 10% C0 2 for 4-6 h, the transfected cells are rinsed in basal media, and resuspended in the same solution at a concentration of 10 6 -10 7 cells/ml. The solution containing the transfected cells is then injected back into an appropriate brain site for therapy. In animal subjects, a repeat biopsy is used to confirm expression. Where the repeat biopsy is inappropriate, a sample of cells is retained for culture to confirm expression. Expression of nerve growth factor is demonstrated by an Elisa procedure using monoclonal antibody to nerve growth factor as a binding agent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention se rapporte à un procédé d'apport d'un polypeptide à l'intérieur d'une cellule d'un vertébré ex vivo et consistant à retirer des cellules vivantes du vertébré, à mettre en contact les cellules avec une préparation contenant une quantité efficace de polynucléotide codant fonctionnellement pour le polypeptide et un lipide utile pour acheminer le polynucléotide dans les cellules puis à geler et à replacer les cellules dans le vertébré 48 heures après la mise en contact de manière que les cellules expriment le polynucléotide in vivo. Le procédé consiste en outre à séparer les cellules de la matrice extracellulaire environnante.
PCT/US1993/000492 1992-01-23 1993-01-21 Transfert de genes ex vivo WO1993014778A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP5513303A JPH07503372A (ja) 1992-01-23 1993-01-21 生体外遺伝子導入
CA 2128616 CA2128616A1 (fr) 1992-01-23 1993-01-21 Transfert de genes ex vivo
EP93904539A EP0625049A4 (fr) 1992-01-23 1993-01-21 Transfert de genes ex vivo.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82437092A 1992-01-23 1992-01-23
US07/824,370 1992-01-23

Publications (1)

Publication Number Publication Date
WO1993014778A1 true WO1993014778A1 (fr) 1993-08-05

Family

ID=25241222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/000492 WO1993014778A1 (fr) 1992-01-23 1993-01-21 Transfert de genes ex vivo

Country Status (4)

Country Link
EP (1) EP0625049A4 (fr)
JP (1) JPH07503372A (fr)
CA (1) CA2128616A1 (fr)
WO (1) WO1993014778A1 (fr)

Cited By (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0667791A1 (fr) * 1991-08-22 1995-08-23 The Board Of Trustees Of The Leland Stanford Junior University Isolement, croissance, differenciation et manipulation genetique de cellules musculaires humaines
WO1996040962A1 (fr) * 1995-06-07 1996-12-19 Megabios Corporation Complexes lipide cationique/adn pour ciblage genique
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5770580A (en) * 1992-04-13 1998-06-23 Baylor College Of Medicine Somatic gene therapy to cells associated with fluid spaces
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US6075012A (en) * 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
WO2002066076A1 (fr) * 2001-02-21 2002-08-29 Melbourne Neuromuscular Research Institute Procede de traitement et agents utiles associes
US6569450B1 (en) 1997-08-13 2003-05-27 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
US6858431B2 (en) 1997-07-30 2005-02-22 Medtronic Sofamor Danek Bone mineralization proteins, DNA, vectors expression systems
WO2005016376A1 (fr) * 2003-08-05 2005-02-24 Curevac Gmbh Transfection de globules sanguins avec un arnm pour l'immunostimulation et la therapie genique
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US7105331B2 (en) 1996-07-03 2006-09-12 Genetics Institute, Llc ICE/CED-3 like protease designated FMH-1
US7145039B2 (en) 1998-11-12 2006-12-05 Invitrogen Corp. Transfection reagents
WO2008020335A2 (fr) 2006-06-09 2008-02-21 Novartis Ag Compositions immunogènes pour streptococcus agalactiae
US7384923B2 (en) 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes
EP1935979A2 (fr) 1999-07-14 2008-06-25 Novartis Vaccines and Diagnostics S.r.l. Peptides de méningococcie antigène
EP1953243A2 (fr) 2000-06-15 2008-08-06 Novartis Vaccines and Diagnostics, Inc. Polynucléotides liés au cancer du colon
EP2058408A2 (fr) 2003-02-14 2009-05-13 Sagres Discovery, Inc. Cibles GPCR thérapeutiques dans le cancer
EP2062591A1 (fr) 2005-04-07 2009-05-27 Novartis Vaccines and Diagnostics, Inc. CACNA1E pour la détection et le traitement de diagnostic du cancer
EP2075346A2 (fr) 2002-01-08 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Produits géniques à expression différenciée dans des cellules cancereuses du sein et méthodes d'utilisation associées
EP2083088A2 (fr) 2005-04-07 2009-07-29 Novartis Vaccines and Diagnostics, Inc. Gènes associés au cancer
EP2093233A1 (fr) 2002-03-21 2009-08-26 Sagres Discovery, Inc. Nouvelles compositions et nouveaux procédés pour le cancer
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
EP2204376A2 (fr) 2004-07-20 2010-07-07 Sagres Discovery, Inc. Nouvelles cibles thérapeutiques dans le cancer
EP2210945A2 (fr) 1998-01-14 2010-07-28 Novartis Vaccines and Diagnostics S.r.l. Antigènes de Neisseria meningitidis
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US7776523B2 (en) 2000-12-07 2010-08-17 Novartis Vaccines And Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
US7790696B2 (en) 1996-09-13 2010-09-07 Lipoxen Technologies Limited Cationic liposomes containing immune response generating moieties
US7816076B2 (en) 2003-02-14 2010-10-19 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2010126370A2 (fr) 2009-04-29 2010-11-04 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Moyens et procédés pour contrebalancer, prévenir et/ou déterminer une insuffisance cardiaque, ou un risque d'insuffisance cardiaque
EP2251424A1 (fr) 1999-05-19 2010-11-17 Novartis Vaccines and Diagnostics S.r.l. Peptides antigeniques de Neisseria
EP2261352A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2267005A1 (fr) 2003-04-09 2010-12-29 Novartis Vaccines and Diagnostics S.r.l. Toxine ADP-ribosylante de Listeria monocytogenes
EP2270175A1 (fr) 2001-03-27 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines de Streptococcus pneumoniae
EP2275129A2 (fr) 2000-01-17 2011-01-19 Novartis Vaccines and Diagnostics S.r.l. Vaccin omv complèté contre la méningocoque
EP2275551A2 (fr) 1999-10-29 2011-01-19 Novartis Vaccines and Diagnostics S.r.l. Peptides antigéniques de Neisseria
EP2277894A1 (fr) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
EP2278006A2 (fr) 1997-11-06 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Antigènes de Neisseria
EP2278007A1 (fr) 1999-04-30 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Antigènes conservés de Neisseria
EP2279746A2 (fr) 2002-11-15 2011-02-02 Novartis Vaccines and Diagnostics S.r.l. Proteines de surface de neisseria meningitidis
EP2298796A2 (fr) 2001-03-27 2011-03-23 Novartis Vaccines and Diagnostics S.r.l. Protéines et acides nucléiques de Staphylococcus aureus
EP2302039A1 (fr) 2002-06-13 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Particules de type virus comprenant le polypeptide gag de HML-2
WO2011056073A2 (fr) 2009-11-04 2011-05-12 Erasmus University Medical Center Rotterdam Composés inédits capables de moduler la néovascularisation et méthodes de traitement faisant appel à ces composés
EP2335724A1 (fr) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation contre la Chlamydia trachomatis
WO2011120474A1 (fr) 2010-04-01 2011-10-06 Centro De Ingeniería Genética Y Biotecnología Méthode pour inhiber la réplication du vih dans des cellules de mammifères et chez l'homme
EP2390346A1 (fr) 2010-05-28 2011-11-30 Universiteit Twente Marqueurs d'ostéoarthrose
WO2012105826A1 (fr) 2011-02-01 2012-08-09 Erasmus University Medical Center Rotterdam Utilisation de microarn dans le diagnostic et la thérapie du vieillissement
WO2013119880A1 (fr) 2012-02-07 2013-08-15 Global Bio Therapeutics Usa, Inc. Procédé compartimenté d'administration d'acide nucléique et ses compositions et utilisations
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
EP2865754A1 (fr) 1999-06-14 2015-04-29 BP Corporation North America Inc. Réassemblage par ligature synthétique dans une évolution dirigée
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9155788B2 (en) 2001-12-19 2015-10-13 Curevac Gmbh Application of mRNA for use as a therapeutic against tumour diseases
US9181319B2 (en) 2010-08-06 2015-11-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9267163B2 (en) 2000-02-28 2016-02-23 Glaxosmithkline Biologicals Sa Hybrid expression of neisserial proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US10064934B2 (en) 2015-10-22 2018-09-04 Modernatx, Inc. Combination PIV3/hMPV RNA vaccines
US10064935B2 (en) 2015-10-22 2018-09-04 Modernatx, Inc. Human cytomegalovirus RNA vaccines
US10124055B2 (en) 2015-10-22 2018-11-13 Modernatx, Inc. Zika virus RNA vaccines
US10188748B2 (en) 2001-06-05 2019-01-29 Curevac Ag Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions
US10195156B2 (en) 2015-12-22 2019-02-05 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
US10266485B2 (en) 2015-09-17 2019-04-23 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US10273269B2 (en) 2017-02-16 2019-04-30 Modernatx, Inc. High potency immunogenic zika virus compositions
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
US10449244B2 (en) 2015-07-21 2019-10-22 Modernatx, Inc. Zika RNA vaccines
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
US10695419B2 (en) 2016-10-21 2020-06-30 Modernatx, Inc. Human cytomegalovirus vaccine
US10815291B2 (en) 2013-09-30 2020-10-27 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10857105B2 (en) 2017-03-15 2020-12-08 MordernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US10898584B2 (en) 2013-11-01 2021-01-26 Curevac Ag Modified RNA with decreased immunostimulatory properties
US11066355B2 (en) 2019-09-19 2021-07-20 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11203569B2 (en) 2017-03-15 2021-12-21 Modernatx, Inc. Crystal forms of amino lipids
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US11364032B2 (en) 2013-08-08 2022-06-21 Global Bio Therapeutics, Inc. Clamp device for minimally invasive procedures and uses thereof
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US11497807B2 (en) 2017-03-17 2022-11-15 Modernatx, Inc. Zoonotic disease RNA vaccines
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
US11969506B2 (en) 2017-03-15 2024-04-30 Modernatx, Inc. Lipid nanoparticle formulation
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Biotechniques, Volume 6, No. 7, issued 1988, MANNINO et al.: "Liposome Mediated Gene Transfer", pages 682-690, see entire article. *
Cancer Research, Volume (supplement) 51, issued 15 September 1991, ROSENBERG et al.: "Immunotherapy and Gene Therapy of Cancer", pages 5074s-5079s, see entire article. *
Molecular Cellular Biology, Volume 4, No. 6, issued June 1984, KAWAI et al.: "New Procedure for DNA Transfection with Polycation and Dimethyl Sulfoxide", pages 1172-1174, see entire article. *
Proceedings of the National Academy of Sciences, Volume 85, issued May 1988, St. LOUIS et al.: "An Alternative Approach to Somatic Cell Gene Therapy", pages 3150-3154, see entire article. *
Proceedings of the National Academy of Sciences, Volume 86, issued November 1989, WOLFF et al.: "Grafting Fibroblast Genetically Modified to Produce L-dopa in a Rat Model of Parkinson Disease", pages 9011-9014, see entire article. *
Science, Volume 254, issued 06 December 1991, BARR et al.: "Systemic Delivery of Recombinant Proteins by Genetically Modified Myoblasts", pages 1507-1509, see entire article. *
See also references of EP0625049A4 *

Cited By (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0667791A4 (fr) * 1991-08-22 1996-05-08 Univ Leland Stanford Junior Isolement, croissance, differenciation et manipulation genetique de cellules musculaires humaines.
EP0667791A1 (fr) * 1991-08-22 1995-08-23 The Board Of Trustees Of The Leland Stanford Junior University Isolement, croissance, differenciation et manipulation genetique de cellules musculaires humaines
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5770580A (en) * 1992-04-13 1998-06-23 Baylor College Of Medicine Somatic gene therapy to cells associated with fluid spaces
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US7687070B2 (en) 1994-02-11 2010-03-30 Life Technologies Corporation Reagents for intracellular delivery of macromolecules
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US6075012A (en) * 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
US6344446B1 (en) 1995-06-07 2002-02-05 Valentis, Inc. Cationic lipid:DNA complexes for gene targeting
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
WO1996040962A1 (fr) * 1995-06-07 1996-12-19 Megabios Corporation Complexes lipide cationique/adn pour ciblage genique
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
US7105331B2 (en) 1996-07-03 2006-09-12 Genetics Institute, Llc ICE/CED-3 like protease designated FMH-1
US7790696B2 (en) 1996-09-13 2010-09-07 Lipoxen Technologies Limited Cationic liposomes containing immune response generating moieties
US6858431B2 (en) 1997-07-30 2005-02-22 Medtronic Sofamor Danek Bone mineralization proteins, DNA, vectors expression systems
US6569450B1 (en) 1997-08-13 2003-05-27 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
US6572881B1 (en) 1997-08-13 2003-06-03 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
US7214384B2 (en) 1997-08-13 2007-05-08 Novartis Vaccines And Diagnostics, Inc. Lipid-conjugated polyamide compounds
EP2278006A2 (fr) 1997-11-06 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Antigènes de Neisseria
US7655245B2 (en) 1997-11-06 2010-02-02 Novartis Ag Neisserial antigens
US8293251B2 (en) 1997-11-06 2012-10-23 Novartis Ag Neisserial antigens
EP2278011A2 (fr) 1998-01-14 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Antigène de neisseria meningitidis
EP2210945A2 (fr) 1998-01-14 2010-07-28 Novartis Vaccines and Diagnostics S.r.l. Antigènes de Neisseria meningitidis
EP2261351A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261347A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261344A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261339A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261348A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261345A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261346A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261355A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261352A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261354A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261353A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261350A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261338A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261343A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261340A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261357A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261349A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261342A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261341A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261356A2 (fr) 1998-05-01 2010-12-15 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
US7166745B1 (en) 1998-11-12 2007-01-23 Invitrogen Corporation Transfection reagents
US7601872B2 (en) 1998-11-12 2009-10-13 Life Technologies Corporation Transfection reagents
US7470817B2 (en) 1998-11-12 2008-12-30 Invitrogen Corporation Transfection reagents
US7479573B2 (en) 1998-11-12 2009-01-20 Invitrogen Corporation Transfection reagents
US7323594B2 (en) 1998-11-12 2008-01-29 Invitrogen Corporation Transfection reagents
US7173154B2 (en) 1998-11-12 2007-02-06 Invitrogen Corp. Transfection reagents
US9358300B2 (en) 1998-11-12 2016-06-07 Life Technologies Corporation Transfection reagents
US7145039B2 (en) 1998-11-12 2006-12-05 Invitrogen Corp. Transfection reagents
EP2290083A1 (fr) 1999-04-30 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Antigènes conservés de Neisseria
EP2278007A1 (fr) 1999-04-30 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Antigènes conservés de Neisseria
US7384923B2 (en) 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes
EP2251424A1 (fr) 1999-05-19 2010-11-17 Novartis Vaccines and Diagnostics S.r.l. Peptides antigeniques de Neisseria
EP2865754A1 (fr) 1999-06-14 2015-04-29 BP Corporation North America Inc. Réassemblage par ligature synthétique dans une évolution dirigée
EP1935979A2 (fr) 1999-07-14 2008-06-25 Novartis Vaccines and Diagnostics S.r.l. Peptides de méningococcie antigène
EP2275551A2 (fr) 1999-10-29 2011-01-19 Novartis Vaccines and Diagnostics S.r.l. Peptides antigéniques de Neisseria
EP2275552A2 (fr) 1999-10-29 2011-01-19 Novartis Vaccines and Diagnostics S.r.l. Peptides antigéniques de Neisseria
EP2275553A2 (fr) 1999-10-29 2011-01-19 Novartis Vaccines and Diagnostics S.r.l. Peptides antigéniques de Neisseria
EP2275554A2 (fr) 1999-10-29 2011-01-19 Novartis Vaccines and Diagnostics S.r.l. Peptides antigéniques de Neisseria
EP2975127A1 (fr) 1999-10-29 2016-01-20 GlaxoSmithKline Biologicals SA Peptites antigènes de neisseria
EP2281571A2 (fr) 2000-01-17 2011-02-09 Novartis Vaccines and Diagnostics S.r.l. Vaccin OMV contre le méningoccoque contenant des protéines membranaires
EP2281570A2 (fr) 2000-01-17 2011-02-09 Novartis Vaccines and Diagnostics S.r.l. Vaccin OMV contre le méningocoque contenant des vésicules membranaires
EP2275129A2 (fr) 2000-01-17 2011-01-19 Novartis Vaccines and Diagnostics S.r.l. Vaccin omv complèté contre la méningocoque
EP2289545A2 (fr) 2000-01-17 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Vaccin OMV contre le méningocoque
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US9267163B2 (en) 2000-02-28 2016-02-23 Glaxosmithkline Biologicals Sa Hybrid expression of neisserial proteins
US8221983B2 (en) 2000-06-02 2012-07-17 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
EP1953243A2 (fr) 2000-06-15 2008-08-06 Novartis Vaccines and Diagnostics, Inc. Polynucléotides liés au cancer du colon
EP2284183A1 (fr) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
EP2277896A1 (fr) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
EP2896629A1 (fr) 2000-10-27 2015-07-22 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines de streptocoques des groupes A et B
EP2284181A1 (fr) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
EP2284182A1 (fr) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
EP2277894A1 (fr) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
EP2277895A1 (fr) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
EP2339035A1 (fr) 2000-12-07 2011-06-29 Novartis Vaccines and Diagnostics, Inc. Rétrovirus endogène régulé en hausse dans le cancer de la prostate
EP2336368A1 (fr) 2000-12-07 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Rétrovirus endogène à régulation positive dans le cancer de la prostate
US7776523B2 (en) 2000-12-07 2010-08-17 Novartis Vaccines And Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
WO2002066076A1 (fr) * 2001-02-21 2002-08-29 Melbourne Neuromuscular Research Institute Procede de traitement et agents utiles associes
EP2270177A1 (fr) 2001-03-27 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines de Streptococcus pneumoniae
EP2298796A2 (fr) 2001-03-27 2011-03-23 Novartis Vaccines and Diagnostics S.r.l. Protéines et acides nucléiques de Staphylococcus aureus
EP2278008A2 (fr) 2001-03-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines de Streptococcus pneumoniae
EP2270176A1 (fr) 2001-03-27 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines de Streptococcus pneumoniae
EP2278010A1 (fr) 2001-03-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines de Streptococcus pneumoniae
EP2278009A1 (fr) 2001-03-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines de Streptococcus pneumoniae
EP2314697A1 (fr) 2001-03-27 2011-04-27 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines de Streptococcus pneumoniae
EP2270175A1 (fr) 2001-03-27 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines de Streptococcus pneumoniae
US11135312B2 (en) 2001-06-05 2021-10-05 Curevac Ag Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions
US10188748B2 (en) 2001-06-05 2019-01-29 Curevac Ag Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions
US11369691B2 (en) 2001-06-05 2022-06-28 Curevac Ag Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions
US10568972B2 (en) 2001-06-05 2020-02-25 Curevac Ag Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions
EP2335723A1 (fr) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation contre la Chlamydia trachomatis
EP2335724A1 (fr) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation contre la Chlamydia trachomatis
US9433670B2 (en) 2001-12-19 2016-09-06 Curevac Ag Application of mRNA for use as a therapeutic against tumour diseases
US9439956B2 (en) 2001-12-19 2016-09-13 Curevac Ag Application of mRNA for use as a therapeutic against tumour diseases
US9655955B2 (en) 2001-12-19 2017-05-23 Curevac Ag Application of mRNA for use as a therapeutic against tumour diseases
US9463228B2 (en) 2001-12-19 2016-10-11 Curevac Ag Application of mRNA for use as a therapeutic against tumour diseases
US9155788B2 (en) 2001-12-19 2015-10-13 Curevac Gmbh Application of mRNA for use as a therapeutic against tumour diseases
US9433669B2 (en) 2001-12-19 2016-09-06 Curevac Ag Application of mRNA for use as a therapeutic against tumor diseases
EP2075346A2 (fr) 2002-01-08 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Produits géniques à expression différenciée dans des cellules cancereuses du sein et méthodes d'utilisation associées
EP2093233A1 (fr) 2002-03-21 2009-08-26 Sagres Discovery, Inc. Nouvelles compositions et nouveaux procédés pour le cancer
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
EP2302039A1 (fr) 2002-06-13 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Particules de type virus comprenant le polypeptide gag de HML-2
EP2279746A2 (fr) 2002-11-15 2011-02-02 Novartis Vaccines and Diagnostics S.r.l. Proteines de surface de neisseria meningitidis
EP2058408A2 (fr) 2003-02-14 2009-05-13 Sagres Discovery, Inc. Cibles GPCR thérapeutiques dans le cancer
US7816076B2 (en) 2003-02-14 2010-10-19 Sagres Discovery, Inc. Therapeutic targets in cancer
EP2267005A1 (fr) 2003-04-09 2010-12-29 Novartis Vaccines and Diagnostics S.r.l. Toxine ADP-ribosylante de Listeria monocytogenes
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
EP2229953A1 (fr) * 2003-08-05 2010-09-22 CureVac GmbH Transfection de cellules sanguines à l'aide de ARNm pour la stimulation immunitaire et la thérapie génique
EP1938833A1 (fr) * 2003-08-05 2008-07-02 CureVac GmbH Transfection de cellules sanguines à l'aide de ARNm pour la stimulation immunitaire et la thérapie génique
EP2223700A1 (fr) * 2003-08-05 2010-09-01 CureVac GmbH Transfection de cellules sanguines à l'aide de ARNm pour la stimulation immunitaire et la thérapie génique
WO2005016376A1 (fr) * 2003-08-05 2005-02-24 Curevac Gmbh Transfection de globules sanguins avec un arnm pour l'immunostimulation et la therapie genique
EP2204376A2 (fr) 2004-07-20 2010-07-07 Sagres Discovery, Inc. Nouvelles cibles thérapeutiques dans le cancer
EP2062591A1 (fr) 2005-04-07 2009-05-27 Novartis Vaccines and Diagnostics, Inc. CACNA1E pour la détection et le traitement de diagnostic du cancer
EP2083088A2 (fr) 2005-04-07 2009-07-29 Novartis Vaccines and Diagnostics, Inc. Gènes associés au cancer
WO2008020335A2 (fr) 2006-06-09 2008-02-21 Novartis Ag Compositions immunogènes pour streptococcus agalactiae
EP2907879A2 (fr) 2009-04-29 2015-08-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Moyens et procédés pour combattre, prévenir et/ou déterminer une insuffisance cardiaque, ou un risque d'insuffisance cardiaque
WO2010126370A2 (fr) 2009-04-29 2010-11-04 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Moyens et procédés pour contrebalancer, prévenir et/ou déterminer une insuffisance cardiaque, ou un risque d'insuffisance cardiaque
WO2011056073A2 (fr) 2009-11-04 2011-05-12 Erasmus University Medical Center Rotterdam Composés inédits capables de moduler la néovascularisation et méthodes de traitement faisant appel à ces composés
US10434137B2 (en) 2010-04-01 2019-10-08 Centro De Ingenieria Genetica Y Biotecnologia Method for inhibiting HIV replication in mammal and human cells
WO2011120474A1 (fr) 2010-04-01 2011-10-06 Centro De Ingeniería Genética Y Biotecnología Méthode pour inhiber la réplication du vih dans des cellules de mammifères et chez l'homme
US9205128B2 (en) 2010-04-01 2015-12-08 Centro De Ingenieria Genetica Y Biotechnologia Method for inhibiting HIV replication in mammal and human cells
WO2011149352A1 (fr) 2010-05-28 2011-12-01 Universiteit Twente Marqueurs d'ostéo-arthrite
EP2390346A1 (fr) 2010-05-28 2011-11-30 Universiteit Twente Marqueurs d'ostéoarthrose
US9937233B2 (en) 2010-08-06 2018-04-10 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9181319B2 (en) 2010-08-06 2015-11-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9657295B2 (en) 2010-10-01 2017-05-23 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US10064959B2 (en) 2010-10-01 2018-09-04 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9701965B2 (en) 2010-10-01 2017-07-11 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2012105826A1 (fr) 2011-02-01 2012-08-09 Erasmus University Medical Center Rotterdam Utilisation de microarn dans le diagnostic et la thérapie du vieillissement
US9950068B2 (en) 2011-03-31 2018-04-24 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US10751386B2 (en) 2011-09-12 2020-08-25 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US10022425B2 (en) 2011-09-12 2018-07-17 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9295689B2 (en) 2011-12-16 2016-03-29 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
WO2013119880A1 (fr) 2012-02-07 2013-08-15 Global Bio Therapeutics Usa, Inc. Procédé compartimenté d'administration d'acide nucléique et ses compositions et utilisations
US9821114B2 (en) 2012-02-07 2017-11-21 Global Bio Therapeutics, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
EP3970734A2 (fr) 2012-02-07 2022-03-23 Global Bio Therapeutics, Inc. Procédé compartimenté d'administration d'acide nucléique et ses compositions et utilisations
US9050297B2 (en) 2012-04-02 2015-06-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9587003B2 (en) 2012-04-02 2017-03-07 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9089604B2 (en) 2012-04-02 2015-07-28 Moderna Therapeutics, Inc. Modified polynucleotides for treating galactosylceramidase protein deficiency
US9255129B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1
US9233141B2 (en) 2012-04-02 2016-01-12 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9675668B2 (en) 2012-04-02 2017-06-13 Moderna Therapeutics, Inc. Modified polynucleotides encoding hepatitis A virus cellular receptor 2
US9220792B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides encoding aquaporin-5
US9782462B2 (en) 2012-04-02 2017-10-10 Modernatx, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9814760B2 (en) 2012-04-02 2017-11-14 Modernatx, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9220755B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9828416B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of secreted proteins
US9827332B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
US9216205B2 (en) 2012-04-02 2015-12-22 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9095552B2 (en) 2012-04-02 2015-08-04 Moderna Therapeutics, Inc. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US9149506B2 (en) 2012-04-02 2015-10-06 Moderna Therapeutics, Inc. Modified polynucleotides encoding septin-4
US9061059B2 (en) 2012-04-02 2015-06-23 Moderna Therapeutics, Inc. Modified polynucleotides for treating protein deficiency
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9114113B2 (en) 2012-04-02 2015-08-25 Moderna Therapeutics, Inc. Modified polynucleotides encoding citeD4
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US11364032B2 (en) 2013-08-08 2022-06-21 Global Bio Therapeutics, Inc. Clamp device for minimally invasive procedures and uses thereof
US10815291B2 (en) 2013-09-30 2020-10-27 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
US10898584B2 (en) 2013-11-01 2021-01-26 Curevac Ag Modified RNA with decreased immunostimulatory properties
US11872285B2 (en) 2014-07-15 2024-01-16 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
US10792362B2 (en) 2014-07-15 2020-10-06 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
US10449244B2 (en) 2015-07-21 2019-10-22 Modernatx, Inc. Zika RNA vaccines
US10702597B2 (en) 2015-07-21 2020-07-07 Modernatx, Inc. CHIKV RNA vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US10442756B2 (en) 2015-09-17 2019-10-15 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US12151995B2 (en) 2015-09-17 2024-11-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US10392341B2 (en) 2015-09-17 2019-08-27 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US11220476B2 (en) 2015-09-17 2022-01-11 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US10266485B2 (en) 2015-09-17 2019-04-23 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US10064935B2 (en) 2015-10-22 2018-09-04 Modernatx, Inc. Human cytomegalovirus RNA vaccines
US11278611B2 (en) 2015-10-22 2022-03-22 Modernatx, Inc. Zika virus RNA vaccines
US10716846B2 (en) 2015-10-22 2020-07-21 Modernatx, Inc. Human cytomegalovirus RNA vaccines
US10702599B2 (en) 2015-10-22 2020-07-07 Modernatx, Inc. HPIV3 RNA vaccines
US11872278B2 (en) 2015-10-22 2024-01-16 Modernatx, Inc. Combination HMPV/RSV RNA vaccines
US10124055B2 (en) 2015-10-22 2018-11-13 Modernatx, Inc. Zika virus RNA vaccines
US10675342B2 (en) 2015-10-22 2020-06-09 Modernatx, Inc. Chikungunya virus RNA vaccines
US10064934B2 (en) 2015-10-22 2018-09-04 Modernatx, Inc. Combination PIV3/hMPV RNA vaccines
US11484590B2 (en) 2015-10-22 2022-11-01 Modernatx, Inc. Human cytomegalovirus RNA vaccines
US10933127B2 (en) 2015-10-22 2021-03-02 Modernatx, Inc. Betacoronavirus mRNA vaccine
US10543269B2 (en) 2015-10-22 2020-01-28 Modernatx, Inc. hMPV RNA vaccines
US12208288B2 (en) 2015-10-22 2025-01-28 Modernatx, Inc. Betacoronavirus RNA vaccines
US10238731B2 (en) 2015-10-22 2019-03-26 Modernatx, Inc. Chikagunya virus RNA vaccines
US10517940B2 (en) 2015-10-22 2019-12-31 Modernatx, Inc. Zika virus RNA vaccines
US10272150B2 (en) 2015-10-22 2019-04-30 Modernatx, Inc. Combination PIV3/hMPV RNA vaccines
US10702600B1 (en) 2015-10-22 2020-07-07 Modernatx, Inc. Betacoronavirus mRNA vaccine
US11235052B2 (en) 2015-10-22 2022-02-01 Modernatx, Inc. Chikungunya virus RNA vaccines
US10383937B2 (en) 2015-10-22 2019-08-20 Modernatx, Inc. Human cytomegalovirus RNA vaccines
US10195156B2 (en) 2015-12-22 2019-02-05 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US10799463B2 (en) 2015-12-22 2020-10-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US11541113B2 (en) 2016-10-21 2023-01-03 Modernatx, Inc. Human cytomegalovirus vaccine
US11197927B2 (en) 2016-10-21 2021-12-14 Modernatx, Inc. Human cytomegalovirus vaccine
US10695419B2 (en) 2016-10-21 2020-06-30 Modernatx, Inc. Human cytomegalovirus vaccine
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US12144895B2 (en) 2016-11-08 2024-11-19 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US10273269B2 (en) 2017-02-16 2019-04-30 Modernatx, Inc. High potency immunogenic zika virus compositions
US10857105B2 (en) 2017-03-15 2020-12-08 MordernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US11203569B2 (en) 2017-03-15 2021-12-21 Modernatx, Inc. Crystal forms of amino lipids
US11969506B2 (en) 2017-03-15 2024-04-30 Modernatx, Inc. Lipid nanoparticle formulation
US11497807B2 (en) 2017-03-17 2022-11-15 Modernatx, Inc. Zoonotic disease RNA vaccines
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
US11207398B2 (en) 2017-09-14 2021-12-28 Modernatx, Inc. Zika virus mRNA vaccines
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
US11597698B2 (en) 2019-09-19 2023-03-07 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US11066355B2 (en) 2019-09-19 2021-07-20 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine

Also Published As

Publication number Publication date
JPH07503372A (ja) 1995-04-13
EP0625049A1 (fr) 1994-11-23
CA2128616A1 (fr) 1993-08-05
EP0625049A4 (fr) 1995-07-12

Similar Documents

Publication Publication Date Title
WO1993014778A1 (fr) Transfert de genes ex vivo
CA2164088C (fr) Plasmides appropries pour la therapie genique
AU692470B2 (en) Adeno-associated viral (AAV) liposomes and methods related thereto
US5783566A (en) Method for increasing or decreasing transfection efficiency
EP0649464B1 (fr) Transfection de cellules de vertebres, par exemple par recombinaison homologue
AU710170B2 (en) Cationic virosomes as transfer system for genetic material
US20030032615A1 (en) Lipid-mediated polynucleotide administration to deliver a biologically active peptide and to induce a cellular immune response
US20040132683A1 (en) Expression of exogenous polynucleotide sequences in a vertebrate
CA2357538A1 (fr) Expression des sequences pollynocleotides exogenes chez un vertebre
CA2227065A1 (fr) Liposomes viraux adeno-associes et leur utilisation pour la transfection de cellules dendritiques pour stimuler l'immunite specifique
JP2021193893A (ja) 改変型ｐｉｇｇｙＢａｃトランスポゼースのポリペプチド、それをコードするポリヌクレオチド、導入キャリア、キット、細胞のゲノムに目的配列を組込む方法及び細胞製造方法
EP1007549B1 (fr) Compositions et procedes pour une transfection tres efficace
WO1997034483A1 (fr) Procedes pour augmenter ou diminuer l'efficacite d'une transfection
WO1997041243A9 (fr) Systeme d'expression cytoplasmique de gene mettant en application un autogene procaryote d'arn polymerase
WO2024156053A1 (fr) Vaccins à base d'acide nucléique contre le virus varicelle-zona (vzv)
WO2024165146A1 (fr) Cellules effectrices immunitaires exprimant de manière stable et transitoire des acides nucléiques
CN118754994A (zh) 表达Lamp2b-CXCR4融合蛋白的骨髓间充质干细胞来源外泌体及其应用
O’MALLEY JR et al. Department of Otolaryngology-Head & Neck Surgery, Johns Hopkins University, PO Box 41402, Baltimore, MD 21203–6402, USA
KR20030078115A (ko) 펩타이드 유전자 전달매체 및 이를 이용한 유전자 전달 방법
JPH07509217A (ja) 治療物質を脳に送出する方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2128616

Country of ref document: CA

Ref document number: 1993904539

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993904539

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993904539

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载